What is CAP?
Founded in 1993, the Corporate AACE Partnership (CAP) is a forum whose purpose is to develop an open dialogue between industry and AACE in the furtherance of patient care. The mission of the CAP is to facilitate the improvement of endocrine patient care by working with industry in areas of mutual interest.
Current Partners
Abbott Diabetes Care
AbbVie
AKCEA Therapeutics
Amarin Pharma Inc.
Amgen
AstraZeneca
Boehringer Ingelheim Pharmaceuticals, Inc.
Corcept Therapeutics
Dexcom, Inc.
Health Monitor Network
Horizon Pharma
Insulet Corporation
Intarcia Therapeutics, Inc.
Lexicon Pharmaceuticals
Lilly USA, LLC
Mannkind Corporation
Medtronics, Inc
Merck
Merck-Pfizer Diabetes Collaboration
Novo Nordisk
Pfizer
PhRMA
Quest Diagnostics
Radius Health
Sanofi
Senseonics Inc
Strongbridge Biophama
Takeda Pharmaceuticals U.S.A, Inc.
Veracyte, Inc.
Xeris Pharmaceuticals
To learn more about the CAP or to request more details about joining the CAP, e-mail cap@aace.com.